Finch Therapeutics Group Inc
OTC:FNCH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Finch Therapeutics Group Inc
OTC:FNCH
|
US |
Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Somerville, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2021-03-19. The firm leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. The company is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). The company is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Somerville, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2021-03-19. The firm leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. The company is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). The company is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.
